Roche to investigate if drug can prevent Alzheimer's
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement.
Trontinemab is designed so the drug is transported across the blood brain barrier - protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US.
Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Swiss drugmaker Roche plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms as a part of the company's growing development program for the disease.
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement.
Trontinemab is designed so the drug is transported across the blood brain barrier - protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US.
Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Swiss drugmaker Roche plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms as a part of the company's growing development program for the disease.
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement.
Trontinemab is designed so the drug is transported across the blood brain barrier - protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US.
Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Swiss drugmaker Roche plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms as a part of the company's growing development program for the disease.
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement.
Trontinemab is designed so the drug is transported across the blood brain barrier - protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the US.
Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
18 hours ago
- Perth Now
Young mum, 29, shares heartbreaking wish after her shock Alzheimer's diagnosis
Single mother Erin Kelly received a life-changing diagnosis in June. But the 29-year-old from Eagleby, Queensland, has known since she was a teenager that one day Alzheimer's disease, which is the most common cause of dementia, could come for her. 'My mum died of Alzheimer's when she was 50,' Kelly told 'The disease took my grandfather at 45, and my aunt when she was the same age. 'I just didn't think it would come for me so soon.' In May 2024, tests confirmed Kelly had inherited a rare genetic mutation called PSEN1 from her mother, Robyne. Carriers of the genetic mutation are at high risk of developing Alzheimer's disease — a progressive brain condition that causes memory loss and cognitive decline — often before the age of 65. Erin Kelly and her eight-year-old daughter, Evie. Credit: Supplied Erin Kelly as a young girl with her mother, who was also diagnosed with Alzheimer's disease. Credit: Supplied In June, scans revealed the first signs of damage to Kelly's neurons, which are cells in the brain that carry messages. When the mum-of-one was given the official diagnosis of early onset Alzheimer's, Kelly says, 'I was in a bit of denial at first'. While dementia can happen to anybody, it is most common after the age of 65. A diagnosis of any kind of dementia when you're younger than 65 is called early onset dementia, or younger onset dementia, and is extremely rare. While Kelly's doctors can't say how quickly the disease will progress, it will soon begin to affect her memory, thinking and behaviour, with her condition expected to deteriorate over time. 'I've started to notice small changes already,' Kelly said. 'Forgetting words and mixing words together. 'I'll be thinking of something, and I'll just mush the words together. 'It's things I didn't do previously.' There is no cure, but Kelly is determined to spend the time she has left making lasting memories for her daughter, Evie, 8. 'We're not exactly sure how or what to tell her yet. She's still so young,' Kelly explained. 'She will get some information, but we want to protect her for as long as we can. 'The goal is to see her finish school, get married. 'I want to make sure she's an adult before I die.' Erin's stepsister Jessica Simpson has set up a Go Fund Me page for Kelly to raise money for a treatment called lecanemab (LEQEMBI). Erin Kelly and her stepsister Jessica Simpson, with their daughters, Evie, 8, and Dallas, 6. Credit: Supplied Erin Kelly is determined to spend the time she has left making lasting memories for her eight-year-old daughter Evie. Credit: Supplied The treatment could help slow down how quickly the disease progresses. In October 2024, the TGA made the decision not to register the medication in Australia, meaning 18 months of treatment could cost Kelly up to $90,000. 'Even with a confirmed diagnosis, Erin has been told she's too young to qualify for clinical trials in Australia,' Simpson explained. 'This treatment could give her more time to keep working, keep functioning and most importantly, keep being Evie's mum for as long as she can.' According to Dementia Australia, dementia is the term used to describe the symptoms of a large group of illnesses which cause a progressive decline in a person's functioning. It is a broad term used to describe a loss of memory, intellect, rationality, social skills and physical functioning. There are many types of dementia, including Alzheimer's disease, vascular disease, frontotemporal dementia and Lewy body disease. Today, there are roughly 433,000 Australians living with dementia and there are an estimated 29,000 people living with younger onset dementia, which can include people in their 30s, 40s and 50s. 'Most people don't associate Alzheimer's with someone so young,' Jessica said. 'Someone still packing school lunches, doing bedtime stories and showing up every day for their child. 'But this is Erin's reality. And sadly, it's progressing fast.'
7NEWS
a day ago
- 7NEWS
Young mum, 29, diagnosed with Alzheimer's disease shares heartbreaking wish to see her daughter finish school
Single mother Erin Kelly received a life-changing diagnosis in June. But the 29-year-old from Eagleby, Queensland, has known since she was a teenager that one day Alzheimer's disease, which is the most common cause of dementia, could come for her. 'My mum died of Alzheimer's when she was 50,' Kelly told 'The disease took my grandfather at 45, and my aunt when she was the same age. 'I just didn't think it would come for me so soon.' In May 2024, tests confirmed Kelly had inherited a rare genetic mutation called PSEN1 from her mother, Robyne. Carriers of the genetic mutation are at high risk of developing Alzheimer's disease — a progressive brain condition that causes memory loss and cognitive decline — often before the age of 65. In June, scans revealed the first signs of damage to Kelly's neurons, which are cells in the brain that carry messages. When the mum-of-one was given the official diagnosis of early onset Alzheimer's, Kelly says, 'I was in a bit of denial at first'. While dementia can happen to anybody, it is most common after the age of 65. A diagnosis of any kind of dementia when you're younger than 65 is called early onset dementia, or younger onset dementia, and is extremely rare. While Kelly's doctors can't say how quickly the disease will progress, it will soon begin to affect her memory, thinking and behaviour, with her condition expected to deteriorate over time. 'I've started to notice small changes already,' Kelly said. 'Forgetting words and mixing words together. 'I'll be thinking of something, and I'll just mush the words together. 'It's things I didn't do previously.' There is no cure, but Kelly is determined to spend the time she has left making lasting memories for her daughter, Evie, 8. 'We're not exactly sure how or what to tell her yet. She's still so young,' Kelly explained. 'She will get some information, but we want to protect her for as long as we can. 'The goal is to see her finish school, get married. 'I want to make sure she's an adult before I die.' Erin's stepsister Jessica Simpson has set up a Go Fund Me page for Kelly to raise money for a treatment called lecanemab (LEQEMBI). The treatment could help slow down how quickly the disease progresses. In October 2024, the TGA made the decision not to register the medication in Australia, meaning 18 months of treatment could cost Kelly up to $90,000. 'Even with a confirmed diagnosis, Erin has been told she's too young to qualify for clinical trials in Australia,' Simpson explained. 'This treatment could give her more time to keep working, keep functioning and most importantly, keep being Evie's mum for as long as she can.' According to Dementia Australia, dementia is the term used to describe the symptoms of a large group of illnesses which cause a progressive decline in a person's functioning. It is a broad term used to describe a loss of memory, intellect, rationality, social skills and physical functioning. There are many types of dementia, including Alzheimer's disease, vascular disease, frontotemporal dementia and Lewy body disease. Today, there are roughly 433,000 Australians living with dementia and there are an estimated 29,000 people living with younger onset dementia, which can include people in their 30s, 40s and 50s. 'Most people don't associate Alzheimer's with someone so young,' Jessica said. 'Someone still packing school lunches, doing bedtime stories and showing up every day for their child. 'But this is Erin's reality. And sadly, it's progressing fast.'
Sydney Morning Herald
3 days ago
- Sydney Morning Herald
How much coffee is too much? And should you be drinking decaf instead?
It's a kick-start for the day, a jolt many of us need to power through, and one of the last socially acceptable addictions. It's only when we have to go without coffee that we realise how badly we rely on it. The jitteriness and headaches from caffeine withdrawal can be so overpowering that many of us turn to decaffeinated instead, thinking surely it must be better for our health. But that might not be true, the experts say – not least because decaf coffee is not actually completely caffeine-free. So if you can bear to make the switch to decaf, just how much better will it be for you? What is decaf coffee, and how is it made? Decaffeinated coffee is coffee that has been treated before roasting to strip the caffeine out of it, with 'chemicals like carbon dioxide or by soaking the beans in water', says Dr Carlo La Vecchia, a professor at the University of Milan and expert from the Institute for Scientific Information on Coffee. This water-based method is sometimes referred to as the Swiss method and is thought to preserve the flavour of the beans more fully. The names of other chemicals used in the decaffeination process – such as methylene chloride, a chemical banned from use in paint thinner for its toxicity – might sound alarming. But the amount left in the beans after this process is negligible, La Vecchia says. 'None of them should remain in appreciable amounts.' Loading This process does not completely strip the beans of their caffeine content, however, leaving behind 'around 2 per cent, and in any case less than 3 per cent' of their natural caffeine levels. A normal cup of filter coffee contains about 100mg of caffeine, though the exact amount used will vary by brand, while a decaf filter coffee has closer to 2mg.
